Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA1 | Q09470 | 5/20 | 0.65 |
| ▸ | KCNAB1 | Q14722 | 5/20 | 0.65 |
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulofenur SCHEMBL29359159 | 1.00 | KCNA1 (0.65) | KCNA1KCNAB1CA12CA1CA2 | |
| SCHEMBL8878995 | 0.97 | KCNA1 (0.65) | KCNA1KCNAB1CA12CA1CA2 | |
| SCHEMBL8794803 | 0.88 | CA12 (0.55) | KCNA1KCNAB1CA12CA1CA2 | |
| SCHEMBL8879166 | 0.88 | KCNA1 (0.56) | KCNA1KCNAB1CA12CA1CA2 | |
| SCHEMBL15865553 | 0.87 | RAB9A (0.67) | KCNA1KCNAB1CA12CA1CA2 | |
| SCHEMBL28766991 | 0.87 | NPC1 (0.67) | KCNA1KCNAB1CA12CA1CA2 | |
| Sulofenur SCHEMBL8376567 | 0.87 | KCNA1 (0.52) | KCNA1KCNAB1CA12CA1CA2 | |
| SCHEMBL8793567 | 0.84 | CA12 (0.52) | KCNA1KCNAB1CA12CA1CA2 | |
| SCHEMBL10698263 | 0.84 | KCNA1 (0.55) | KCNA1KCNAB1CA12CA1CA2 | |
| SCHEMBL9486495 | 0.82 | CA12 (0.66) | KCNA1KCNAB1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10447 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | claimed |
| EP-4401780-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | University of Maryland, College Park (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20240002347-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | ALONBIO LTD. (IL) | 2024-01-04 | — | — | US | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1999039732-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-08-12 | — | — | WO | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0382411-B1 | Delivery of cytotoxic agents | LILLY CO ELI (US) | 1994-12-07 | — | — | EP | claimed |
| US-5116874-A | Aminocarbonyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 1992-05-26 | — | — | US | claimed |
| EP-0382411-A2 | Delivery of cytotoxic agents | ELI LILLY AND COMPANY (US) | 1990-08-16 | — | — | EP | claimed |
| EP-0222475-B1 | SULFONYL UREAS WITH ANTI-TUMOUR ACTIVITY | ELI LILLY AND COMPANY (US) | 1989-11-29 | — | — | EP | claimed |
| EP-0222475-A1 | Sulfonyl ureas with anti-tumour activity | ELI LILLY AND COMPANY (US) | 1987-05-20 | — | — | EP | claimed |
| CN-86106428-A | Anti-tumor method and compound thereof | — | 1987-03-18 | — | — | CN | claimed |